Title

- Harmony COVID-19: a ready-to-use kit, low-cost detector, and smartphone app for point-of-care SARS-CoV-2 RNA detection
- Harmony COVID-19: point-of-care SARS-CoV-2 RNA detection

Authors

Nuttada Panpradist[1,2], Enos Kline[1], Robert G Atkinson[1], Michael Roller[1], Qin Wang[1], Ian T Hull[1], Jack H Kotnik[1,3], Amy K Oreskovic[1], Crissa Bennett[1], Daniel Leon[1], Victoria Lyon[3], Shane D Gilligan-Steinberg[1], Peter D Han[4,5], Paul K Drain[6], Lea M Starita[4,5], Matthew J Thompson[3], Barry R Lutz[1]*

AFFILIATIONS

Department of Bioengineering, University of Washington,

Global Health for Women, Adolescents, and Children, School of Public Health, University of Washington,

Department of Family Medicine, University of Washington,

Department of Genome Sciences, University of Washington,

Brotman Baty Institute for Precision Medicine,

Departments of Global Health, Medicine, and Epidemiology, University of Washington, Seattle, WA, USA

* **Corresponding author:** B. R. L. (blutz@uw.edu)

3720 15th Ave NE, Campus Box 355061, Seattle, Washington, United States 98195

Abstract (≤150 words)

RNA amplification tests sensitively detect SARS-CoV-2 infection, but their complexity and cost are prohibitive for expanding COVID-19 testing. We developed "Harmony COVID-19", a point-of-care test using inexpensive consumables, ready-to-use reagents, and a simple device accommodating up to 4 samples simultaneously. Our ready-to-use, multiplexed reverse-transcription, loop-mediated isothermal amplification (RT-LAMP) can detect down to 0.38 SARS-CoV-2 RNA copies/µL and can report in 17 min for high viral load samples (5,000 copies/µL). Harmony detected 97% or 83% of contrived samples with ≥0.5 viral particles/µL in nasal matrix or saliva, respectively. Evaluation in clinical nasal specimens in viral transport media (VTM, n=101) showed 100% detection of RNA extracted from specimens with ≥0.5 SARS-CoV-2 RNA copies/µL, with 100% specificity in specimens positive for other respiratory pathogens. VTM is non-ideal for Harmony system, yet extraction-free analysis (n=29) had 95% success in specimens with ≥1 RNA copies/µL. Usability testing performed first-time by healthcare workers showed 95% accuracy.

Teaser (≤125 characters with period)

A novel four-plexed RT-LAMP test kit operated by health workers can provide faster and more sensitive results than lab tests.

MAIN TEXT (11,642 words; limit 15,000 words)

Introduction

In 2019, an outbreak in China of SARS-CoV-2, the causative pathogen of COVID-19, rapidly became a global pandemic (*1*) and after a year it has infected 100 million

people and killed 2 million people (*2*). Multiple measures have been used to contain the spread of COVID-19. Governments imposed universal "stay-home" orders (*3*) to minimize transmission, which in turn has harmed mental health, social life, and the economy (*4*). Available vaccines do not completely prevent SARS-CoV-2 infections (*5*). Vaccinated individuals with breakthrough infections can transmit SARS-CoV-2 as much as unvaccinated individuals (*6*). Widespread COVID-19 testing and contact tracing is still a solution for sustained re-openings, allowing subsets of a community to resume work and begin to restore the economy. Moreover, testing is essential for the re-opening of international borders. Several countries have enforced a "fit-to-fly" policy; international travelers must test negative for COVID-19 within 72h before boarding international flights (*7*). Fast and sensitive point-of-care (**POC**) testing could facilitate the safe return to functioning domestic and international economies. POC testing could allow testing to expand to geographic regions that have limited access to centralized laboratory facilities, enable essential businesses to regularly test employees, and allow easy and efficient community testing by public health officials and clinics. Importantly, POC testing is critical in settings that require rapid turnaround time such as emergency urgent care facilities and points of introduction such as airports.

Here, we report the development of Harmony COVID-19 — a complete moderate-throughput sample-to-result system for sensitive POC detection of SARS-CoV-2 RNA. Harmony simplifies testing with ready-to-use assay reagents, an easy-to-use dedicated smartphone interface, and an inexpensive isothermal heater/detector device to enable POC testing. The assay includes three redundant SARS-CoV-2 targets to avoid false negatives due to viral mutation and an internal amplification control (**IAC**) in each test to avoid false negatives in case of assay failure. The heater/detector detects two-color real-time fluorescence for the SARS-CoV-2 redundant targets and IAC, and results are automatically reported on the smartphone. We evaluated the system using two panels of specimens - a panel of extracted nasal specimens from individuals with respiratory symptoms, and a panel of contrived specimens from the XPRIZE Rapid COVID Testing competition – and we conducted usability testing of Harmony by healthcare workers (**HCWs**). These evaluations have demonstrated that Harmony is a complete system for sample-to-result testing that is highly accurate in moderate complexity laboratories and clinic-based patient care settings.

RESULTS

Workflow and operation of COVID-19 Harmony
The Harmony test kit and detector were engineered for low-cost and simplicity of use to enable POC testing (**Fig. 1A**). The test involves taking a nasal swab, eluting the swab in a non-toxic buffer, and transferring the buffer to a reaction tube containing ready-to-use reagents. The reagent tube is inserted into the custom-designed heater/reader operated by a cell phone that provides instructions and displays the result. For samples with no target (**Fig. 1B**, left; NTC), detection of the IAC confirms that the reaction was functional; the absence of both target and IAC amplification indicates a failed reaction. For samples with SARS-CoV-2 RNA (**Fig. 1B**, middle; 200 copies/reaction, corresponding to 5 copies/µL), the green signal indicates a positive test, regardless of whether IAC is detected. Harmony using dry reagents detects down to 200 copies of SARS-CoV-2 RNA on a swab (**Fig. 1B**, right; 20

copies/reaction, corresponding to 0.5 copies/µL). Real-time detection reports a positive sample as soon as the target signal appears, allowing detection in <30 min for samples ≥2000 copies per swab (**Fig. 1C**), with earlier results for higher viral load.

Novel modifications of RT-LAMP core assay chemistry

The Harmony assay uses a unique variation of reverse transcription loop-mediated isothermal amplification (**RT-LAMP)** that allows fluorescence detection of multiple targets in the same reaction. The four-plexed assay amplifies three non-overlapping genomic regions (**Fig. 1D**) of the SARS-CoV-2 nucleocapsid phosphoprotein (**N gene**) reported by a green fluorescence signal (**FAM**) and an engineered **IAC** reported by a red fluorescence signal (TEX 615 or Texas Red® - used interchangeably). A positive test result is reported when any of the three SARS-CoV-2 targets are present. Presence of IAC amplification is not necessary in a positive test. A negative test result is reported if SARS-CoV-2 RNA is undetected, and the IAC is detected. If neither target nor IAC is detected, it indicates a test failure, and the result is reported as indeterminate (**IND**). Harmony primers target the SARS-CoV-2 N gene. Based on the initial design process in early 2020, alignments of related coronaviruses (e.g., SARS-COV-1, MERS, bat coronaviruses) confirmed that the N gene was likely to be a well-conserved target (not the most conserved region) but was sufficiently divergent from related species to be organism specific. At the time the sequence diversity of the virus was very low, thus further SARS-CoV-2 specific analysis of the N gene by sequence analysis was not possible. Therefore, primer design decisions were based on performance-driven parameters such as computational estimates of primer properties (e.g., homodimers, hairpin structures, Tm, %GC). Our recent *in-silico* analysis revealed that our primers still have high coverage across new variants (*8*). The specific overlap with the U.S. CDC primers (**Fig. 1D**) was semi-coincidental and possibly a consequence of shared primer design requirements as suitable regions evaluated by analysis software, and the small size of the N gene (1,275bp) relative to the footprint of our LAMP assays (213-281bp). The proximity of our LAMP amplification targets on the same contiguous DNA fragment may have an extra advantage to enable a synergistic initiation effect. Amplification events could occur closely enough such that they could bump each other. Other RT-LAMP technologies (**Table S1**) that amplify different genes would not benefit from this effect. For the IAC amplification, we used a single LAMP loop primer to intentionally impair the IAC amplification (**Table S2**) so that it would not outcompete SARS-CoV-2 amplification.

Harmony also uses novel universal probes containing entirely engineered sequences (*8*). The 5' FAM or 5'TEX 615 signal probes each have a 5' sequence region hybridized to the complementary sequence region of its quencher probe that has 3' Iowa Black FQ or 3' BHQ-2, respectively. In the absence of target or IAC amplification, these quencher molecules remain proximal to their fluorophore pairs and absorb the fluorophore's emission wavelengths. The signal probes each have a 3' overhang with a sequence region identical to the 5' overhang of the loop primer for target or IAC. In the presence of target or IAC amplification, quencher probes are displaced, enabling signal detection.

To facilitate Harmony's multiplexed RT-LAMP, we employed newly developed, strand displacing TFv1 chimeric DNA polymerase. Compared to the WarmStart Bst DNA polymerase 2.0 commonly used in RT-LAMP SARS-CoV-2 assays (**Table S1)**, (*9, 10*), TFv1 chimeric DNA polymerase has a comparable amplification rate in a single-plex RT-LAMP (**Fig. 2A**) but a drastically faster amplification of SARS-CoV-2 (**Fig. 2B**) and IAC targets in our four-plexed RT-LAMP (**Fig. 2C**).

151
Ready-to-use reagents
Our lyophilized RT-LAMP mixture contains primers, sequence-specific fluorescence
probes, IAC DNA template, polymerases, supporting proteins, and co-factors (**Fig.
3A**) and is activated by adding the nasal swab eluate containing additional buffer,
salts, and detergent. We initially screened excipient formulations that can
preserve enzymatic activity and do not significantly interfere with the primer or probe
behaviors. We selected trehalose and mannitol since they have been used as
excipients for PCR (*11-15*) and LAMP (*16*). We found that mannitol did not
drastically impact the Harmony's sensitivity compared to trehalose at the same
concentration (**Fig. S1**) and did not require adjusting the reaction temperature to
maintain the assay speed. Possibly, this is due to the effect of trehalose on altering
primer and probe melting temperatures (*17*).
Using a commercial real-time thermal cycler, lyophilized RT-LAMP detected 3/3
replicates of 15 RNA copies/reaction (0.38 copies/µL), and IAC was detected in all
negative samples (**Fig. 3B**). RT-LAMP amplification of 2×10^5 RNA copies/reaction
using the dry reagents generated detectable signal in 17 min (**Fig. 3C**). We subsequently
tested our in-house lyophilized reagents on a larger number of technical replicates of
SARS-CoV-2 RNA at 20 copies/reaction (0.5 copies/µL) using multiple batches, and
90% (36/40, 95% confidence interval (**CI**): 76 - 97%) were amplified (**Fig. 3D**).
Medians of time to detection for FAM and TEX 615 signals were 28.6 min (range: 28.0
- 29.4) and 31.7 min (range: 31.1 - 32.7), respectively. Based on these preliminary
experiments, our limit of detection (**LOD**) is 15-20 copies/reaction (0.38 - 0.5
copies/µL) when analyzing purified, synthetic SARS-CoV-2 RNA. Next, we tested our
lyophilized RT-LAMP reactions with simulated nasal matrix (salt, mucin, human
DNA) to mimic human nasal samples. We observed a 10-min delay in amplification of
both SARS-CoV-2 RNA and IAC DNA (**Fig. 3E**), but all targets were detected
correctly. Greater interference or other harm to the reaction will further delay IAC
amplification; thus, the IAC serves as an indicator of the reaction's function and can
prevent reporting false negatives due to interference or damaged reagents. By setting a
60-min reaction time, the assay can suffer some delay while still correctly identifying
positive samples. Specificity testing against closely related pathogens MERS and
SARS-CoV-1 showed no cross-reactivity (**Fig. S2**).
184
Hardware: housing and real-time fluorescence reader device
The Harmony system includes a heater/detector device controlled by a dedicated cell
phone and plastic housing with a sample setup station (**Fig. 4A**). The heater/detector
device (**Fig. 4B**) includes an aluminum heater block with four wells and a spring-
loaded heated lid to prevent condensation. A proportional integral derivative (**PID**)
feedback loop running on a microcontroller allows recovery of the temperature
setpoint within 3-4 min after disturbance from opening the lid (**Fig. 4C**). Two LEDs
(**Fig. 4D**) provide the excitation light by shining down through the top of each sample
tube. Fluorescence emission passes through holes drilled on the side of the heater
block. Each sample well has an emission filter/photodiode set on each side to detect
two emission wavelengths (**Fig. 4E**). A blue LED (dominant wavelength 470nm) is
used to excite FAM, and the emission photodiode sits behind a dielectric 550nm
longpass filter. A yellow LED (dominant wavelength 587nm) is used to excite TEX
615, and a second emission photodiode sits behind a 630nm longpass dielectric filter.
199

Thermostable Inorganic Pyrophosphatase enables real-time LAMP detection in the Harmony COVID-19 device

RT-LAMP generates inorganic pyrophosphates (**PPi**) that precipitate from the solution. The cloudiness created by precipitates has been used as a visual readout signal for LAMP (*18*), but here the cloudiness scattered light and caused non-specific signals in NTC samples (**Fig. 4F,** top) when tested on device. Inorganic pyrophosphatase (**TiPP**) can be added to the LAMP reaction to hydrolyze built-up pyrophosphate, and this combination has been used in other contexts to improve differentiation of LAMP products in melt analysis (*19*) and indirectly detect LAMP via phosphate ions hydrolyzed by the TiPP (*20*). In fact, TiPP was advertised for its use for the enhancement of DNA replication (*21*), mitigating pyrophosphorolysis during DNA synthesis for sequencing (*22*). In our context, we added TiPP in the RT-LAMP reaction to eliminate scattered signal from pyrophosphate to prevent non-specific signal in negative reactions (**Fig. 4F,** bottom). Interestingly, this effect was not observed when the reaction was tested in the commercial thermal cycler (BioRad CFX96). This is potentially because the commercial thermal cycler uses bandpass filters for both excitation and emission wavelengths, while our device does not have excitation filters.

In addition to the physical effects, we have postulated that PPi accumulation may inhibit LAMP; as PPi forms, magnesium phosphate precipitate, Mg^{2+}, will be sequestered from the reaction, potentially impairing polymerase activity and primer hybridization. TiPP addition reduces the turbidity that is indicative of magnesium phosphate precipitate, so it may limit the depletion of reaction components. This has implications for multiplexed LAMP reactions, where concurrent amplification of multiple targets is a desired outcome. This possibility or the specific capability of TiPP to "enhance" LAMP has not yet been evaluated.

Multi-purpose Android mobile app: instruction, temperature control, and real-time analysis of results

The phone software provides interactive guidance for setting up the test. It prompts the user to input a sample ID by scanning a barcode, capturing a photo, or typing a sample ID (**Fig. 5, A-D**). The software also carries out the closed-loop temperature control for the heater block and lid heater, and it displays the status of the heater block to prompt the user to insert the reaction tubes only after the heater reaches the reaction temperature (**Fig. 5E**). During the test run, the screen displays the test status ("analysis in progress") and elapsed time, or it reports any detected errors ("failed run") (**Fig. 5F**). Importantly, the software performs real-time data analysis that detects fluorescence intensity rise above a dynamically and automatically computed background level. Signals from SARS-CoV-2 can appear early in the test, especially for high viral loads, and the real-time analysis allows reporting of positive tests immediately after they are detected (**Fig. 5G**). Negative results and IND results are reported at the end of the test run time (**Fig. 5H**). Software analysis is described in the Methods section.

Evaluation Harmony COVID-19 system on contrived SARS-CoV-2 samples (XPRIZE panel) without extraction

A panel of contrived samples from the COVID-19 XPRIZE competition were tested on the Harmony system. For SARS-CoV-2 virus in 1xPBS (**Fig. 6A**), Harmony detected all positive samples containing ≥50 SARS-CoV-2 viral particles/rxn, and 96% of samples containing ≥20 viral particles/rxn. In human nasal matrix (**Fig. 6B**)

and human saliva (**Fig. 6C**), Harmony detected 97% and 83%, respectively, of samples containing ≥20 viral particles/rxn. Harmony had zero false positives across all sample types. Interestingly, unlike the case of simulated nasal matrix (**Fig. 3E**), we did not observe delayed detection time of IAC in human nasal or saliva samples. Detection times (mean ± SD) for IAC amplification in negative samples were 32.9 ± 3.8 min for PBS, 35.8 ± 4.8 min for human nasal matrix, and 34.3 ± 11 min for human saliva, respectively (p>0.05; t-test, two-tailed). It is worth noting that in this experiment RT-LAMP reactions were either set up at room temperature (intended protocol for our assay, hollow symbols) or on ice (protocol used by most EUA RT-LAMP assays as summarized in **Table S1**, solid symbols). Even with a small sample size, we observed relatively delayed reaction and more false negative results when the reaction was set up on ice, especially those near the LoD (*i.e.*, 20 copies/rxn).

Evaluation of clinical specimens using the Harmony COVID-19 system
We first tested the assay for reactivity with SARS-CoV-2 and cross-reactivity with other respiratory pathogens using RNA extracted from infected patient specimens. The retrospective clinical samples had been collected in viral transport medium (VTM), which is not the intended sample type for Harmony, since a POC test uses fresh samples and does not require sample transport. Subsequently, we tested a smaller panel enriched with positive specimens to assess the feasibility of detecting SARS-CoV-2 RNA in VTM specimens without extraction.
Clinical VTM specimens were collected from individuals positive for SARS-CoV-2 (*n = 33*) or for other pathogenic respiratory infections (*n = 68*) and were re-tested by RT-qPCR using CDC primer and probe sequences (*23*) to measure the SARS-CoV-2 viral load and provide the reference test result. Using RT-qPCR with CDC primers/probes, 68 specimens were confirmed to be SARS-CoV-2 negative (**Fig. 7A, left**), 30 specimens were confirmed to be SARS-CoV-2 positive (**Fig. 7A, right**), and three previously positive specimens were only detected by one RT-qPCR assay (either N1 or N2) and classified as inconclusive (**INC, Fig. 7A,** middle).
Specimens were tested in duplicate on Harmony using the ready-to-use reagents (**Fig. 7A)**, amplification curves are arranged from low to high virus concentration as quantified by RT-qPCR assay (**Fig. S8** and **F**ig. **S9**). Out of 30 RT-qPCR-positive specimens, Harmony detected 26 specimens in both technical replicates and 3 specimens in one of the two replicates. In the three RT-qPCR INC results, one sample was detected by Harmony in one of the two replicates. Excluding the RT-qPCR INC specimens and applying a stringent requirement for both Harmony replicates to be detected to report a positive test, Harmony achieved 96% accuracy (94/98, 95%CI: 88-98%), 87% sensitivity (26/30, 95%CI: 69-96%), and 100% specificity (68/68, 95%CI: 94-100%). If replicates are treated independently (**Fig. 7B**), Harmony detected 55/60 positive specimens (92% sensitivity, 95%CI: 82-97%). Harmony detected all positive specimens with ≥20 copies/reaction (0.5 copies/μL). The clinical panel (**Fig. 7A**) included 68 specimens that were SARS-CoV-2 negative but contained other respiratory pathogens including influenza, rhinovirus, and seasonal coronavirus (**Fig. 7C**), as determined using OpenArray (a laboratory PCR test with microarray detection) (*24*). Harmony correctly identified all SARS-CoV-2 negative specimens (**Fig. 7A,** left). **Fig. 7B** summarizes the performance of Harmony on detecting extracted RNA from clinical VTM specimens.
Next, we used Harmony to detect SARS-CoV-2 in VTM specimens without RNA extraction. We expected the presence of microbial agents in the VTM to delay amplification and thus we ran the reaction for additional 30 min. Compared to RT-

qPCR, Harmony with 90-min run time detected 18/24 positive specimens in both replicates and 3/24 in one of the replicates. Considering each replicate independently, Harmony detected 78% (32/41) and 95% (39/41) SARS-CoV-2 RNA positive specimens within 60- and 90-min detection time, respectively. Detection time (mean ± SD) of IAC in the negative samples with direct VTM amplification (43.9 ± 6.4 min) was significantly slower than the detection time with extracted RNA (38.5 ± 1.6 min; p=0.03, t-test, two-tailed). Pair-wise comparison among positive SARS-CoV-2 specimens (**Fig. 7E**) showed two specimens with significantly different detection time. Even though VTM is not the intended sample type, Harmony detected 95% of SARS-CoV-2 VTM specimens that contained at least 1 copy/µL (**Fig. 7F**).

Feasibility testing: sample-to-result system tested by healthcare workers and laboratory personnel

To complete the system, we developed a test kit that included all components needed for running a test, including the swab, elution buffer, a fluid transfer device, and a ready-to-use reagent tube. Swabs were pre-loaded with SARS-CoV-2 DNA to serve as a control sample to evaluate performance by HCWs and laboratory personnel (**LPs**).

In the first phase of user testing (**Fig. 8A**), we compared the accuracy and reproducibility of two methods for transferring the eluate to the reaction tube when operated by LPs *(n = 5)* and HCWs (such as nurses, medical students, and dental students; *n = 10*). The first method (**Fig. 8B** and shown-previously in **Fig. 1**) used a unified sampler-dispenser. The second method (**Fig. 8C**) used a transfer pipette to transfer a fixed volume of fluid to the reaction tube. Regardless of the baseline skill of operators, transfer pipettes yielded more reproducible recovered volumes than the unified dispenser (F-test, p <0.001). Recovered volumes of the two methods were not significantly different between HCWs and LPs (student's t-test, two-sided, p = 0.90; **Fig. 8D**). User feedback on the transfer methods and preferences on tube sizes are summarized in **Table S3**. Next, HCWs and LPs executed the full Harmony workflow on contrived SARS-CoV-2 DNA swab samples (**Fig. 8**). Using the transfer pipette workflow (**Fig. 8E**), the test accuracy was 100% (10/10) for LPs and 95% (19/20) for HCWs. Surprisingly, we found that the HCWs performed better than the LPs when using the unified dispenser system (**Fig. 8F**) when considering both accuracy and IND rates. HCWs had significantly lower (Z-test, two-tailed, p<0.05) IND results (1/20) than LPs (3/10) when using the unified dispenser system. Excluding IND results, the HCWs had 89% accuracy, higher than LPs with 71% accuracy (Z-test, two-tailed, p <0.05), when using the unified dispenser system.

Discussion

This work presents a combination of multi-disciplinary engineering (molecular, mechanical, electrical, software, human interface design) to develop a complete system for SARS-CoV-2 detection at the POC. The system is inexpensive and simple yet has features comparable to laboratory-based tests (**Table 1A**). The assay has high sensitivity and specificity in clinical and contrived specimens, and HCWs successfully performed the workflow with high accuracy.

Harmony uses ready-to-use reagents that enable fast and accurate assay setup while maintaining high assay sensitivity and specificity. The lyophilized Harmony assay detected as low as 15 copies/reaction of synthetic SARS-CoV-2 RNA and detected all

extracted RNA from clinical specimens at ≥20 copies/reaction with no false positives across all sample types. Harmony chemistry is also robust, enabling detection of contrived samples in human nasal matrix (intended sample type) and saliva without RNA extraction. We found excellent sensitivity when testing samples with ≥20 viral particles in nasal matrix (estimated 500 copies/swab for 1mL elution buffer and 40µL reaction). In saliva samples at the same concentrations (not the intended sample type), Harmony showed moderate sensitivity. Heat treatment of saliva shown to enable detection by RT-PCR (25) would likely improve the sensitivity of Harmony with saliva samples. Regardless, our current level of assay sensitivity would be sufficient to detect SARS-CoV-2 in most nasal specimens (~10^3 to ~10^9 copies/swab) (26) or saliva (~10^4 to ~10^8 copies/mL) (27) from infected individuals during the first week after the onset.

Harmony's high assay sensitivity and specificity despite its high multiplexity was made possible by multiple modifications to traditional RT-LAMP. We used novel polymerase and probe design that can specifically discriminate between the SARS-CoV-2 from IAC amplification while most RT-LAMP analysis in tube relies on detection of total amplification and split each RT-LAMP reaction to detect only one target/reaction (**Table S1**). Multi-target amplification is essential to reduce false negatives in SARS-CoV-2 nucleic acid tests as the new variants continue to emerge.

In addition to the core assay, our lyophilization process also involves non-traditional modifications. Unlike other lyophilized RT-LAMP (28), our lyophilized reagents are magnesium-free, which prohibits any enzymatic activity that may occur before assay initiation. Our lyophilized RT-LAMP is activated upon the addition of sample which contains magnesium and detergent. Thus, it should be less prone to moisture degradation than magnesium-containing lyophilized RT-LAMP. Secondly, RT-WarmStart enzyme in Harmony assay is inactive at room-temperature and thus prevented activities during the reaction set up and eliminated the need for setting up the reaction on ice as performed in other SARS-CoV-2 LAMP assays (**Table S1**). Cold temperature can promote dimer and/or secondary structures of LAMP primers, which we observed as a negative impact on the assay sensitivity and speed. In fact, while setting up Harmony assay for lyophilization, RT-LAMP primers and probes were heated and cooled down passively at room temperature to minimize secondary structures prior to mixing with the other components. Last, we removed water to reduce the final volume of lyophilized reaction to 20µL. This enabled doubling the excipient concentrations in the lyophilized pellet and shortens the lyophilization drying time. When testing samples, the excipients are then diluted by half to 40µL reaction, thus reducing any impact of excipients on the core assay function. We anticipate that these components will be stable up to 30 °C but future experiments will be conducted in the final form of the product for future commercialization efforts.

Isothermal amplification, like RT-LAMP in Harmony, is often promoted as ideal for POC testing because it can be carried out using a constant temperature heat source, such as a water bath, heat block, or even more novel sources (chemical heat source, sunlight, body temperature) (29). However, reported tests often have other limitations that may prevent their use in POC testing (**Table 1B**). Common limitations include use of frozen reagent stocks that must be thawed and then formulated using laboratory pipettes, manual steps for sample processing that require laboratory skill, or detection steps that rely heavily on user interpretation or analysis by a user's cell phone.
Harmony is a complete sample-to-result system that uses ready-to-use reagents for simple 1-minute setup and a dedicated device that reports results without extra post-amplification steps or reliance on user interpretation.

Some RT-LAMP tests use end-point lateral flow strips for detection (**Table S1**), which adds a user step, but more importantly, should not be done at the POC because it exposes the testing site to amplicons that will give false positive results in subsequent tests. Others use in-tube detection by eye (*30*) or a cell phone (*31*) which increases the user burden and could introduce additional sources of error. Real-time detection used in Harmony COVID-19 removes the need for extra detection steps or user interpretation. Real-time detection also allows Harmony to report positive results as soon as the SARS-CoV-2 signal appears rather than waiting for an end-point detection method. High viral load samples could be detected in as little as 20 min, which could enable more timely infection control measures to limit viral spread. Harmony real-time detection allows testing without opening tubes after amplification, requires no extra steps or interpretation by the user, and allows reporting a positive sample earlier than end-point detection methods.

The Harmony device automates heating, multiplexed detection, and data interpretation. We integrated a simple heater with low-cost LEDs and sensors to enable real-time two-color detection of RT-LAMP fluorescence in four independent sample wells. The device costs <US$300 in parts for prototypes, while the lowest cost of a commercial RT-PCR machine on the market is >US$5000(*32*). Moreover, the Harmony device is portable and energy-efficient, requiring <15 watts and operable by USB power sources. These features are attractive for use at the POC in the U.S. and resource-limited settings.

Lastly, the simple workflow and analysis of Harmony is appropriate for POC testing. Test operation involves a few simple steps that take ~1 minute, and there are no further user steps after starting the test. Here, HCWs were able to operate the tests with simple written instructions and a video showing the procedures. The simplicity of the Harmony procedure and completeness of the stand-alone system can be a significant advantage for onboarding to ambulatory care settings and potentially community testing locations. Compared to existing US FDA EUA RT-LAMP tests (**Table S1**), Harmony is very competitive. Most RT-LAMP technologies are not designed for use in CLIA-waived settings. Lucira™ is the only product approved for use at the POC, but it is custom-designed to be battery-powered and completely disposable. This strategy, while is convenient for users, can contribute to electronic waste and relatively high cost for producing a unit. In contrast, Harmony relies on low-cost consumables and generates no electronic waste after each run.

In this study, we evaluated the system using contrived specimens in nasal and saliva matrix (XPRIZE) and clinical specimens stored in VTM, which may not reflect the performance in fresh clinical samples. These samples were used due to the difficulty of obtaining fresh dry swabs intended for this POC test. Because VTM is irrelevant for immediate testing at the POC, we tested RNA extracted from clinical samples to assess the overall assay performance on clinical RNA and subsequently tested feasibility of direct amplification of VTM samples. Nevertheless, this testing shows excellent analytical reactivity to clinical specimens, no cross-reactivity with other respiratory pathogens, analytical sensitivity comparable to the CDC RT-PCR, and resilience in the presence of nasal matrix. While our assay is relatively fast and sensitive, there is potential to further improve the performance. We ran RT-LAMP at 64°C, which is 9°C above the optimal temperature for the RT enzyme. We hypothesize that cooling of the heat block when the lid is open, followed by a few minutes to ramp back up to 64°C, provided an opportunity for the RT enzyme to operate. In contrast, the reaction speed of the temperature-stable TFv1 DNA

polymerase in this assay is optimal at higher temperature. Thus, operating the device
with an initial 55°C step for optimal RT activity followed by a higher temperature
step for fast DNA amplification could increase sensitivity and/or speed.

The current design of RT-LAMP assay can be improved to include an IAC that is
more representative of the SARS-CoV-2 virus. We currently use a DNA IAC, which
has been used in several EUA assays, but the DNA control does not capture the
potential failure of the lysis and cDNA conversion processes. We are developing a
new IAC that uses RNA that can be packaged in a viral envelope. This modification
may require re-development of excipients that preserve the RT-LAMP enzymes and
the enveloped RNA.

POC tests like Harmony could provide rapid testing to enable the re-opening of
businesses, schools, and borders; but the need for POC testing extends beyond the
current emergency. As natural immunity and vaccination take hold, COVID-19 is
likely to become endemic with seasonal outbreaks. Tests such as Harmony will be
necessary not only to help identify individuals with SARS-CoV-2, but other
respiratory pathogens such as influenza and RSV, as the symptoms of these are
similar. Prior to the current SARS-CoV-2 pandemic, the yearly influenza infections
caused nearly 30 million cases in the U.S. alone, with 400,000 hospital admission and
35,000 deaths (*33, 34*). Indeed, particularly when more typical patterns of respiratory
infections occur, there will be a need for tests that can perform multiplex testing for
individuals presenting respiratory symptoms. Tests such as Harmony will become a
common practice for confirming presence of viral infections that can be treated with
antiviral therapies or that demand infection control, as well as helping to reduce
inappropriate use of antibiotics. Further, test platforms developed for this pandemic
could be more readily adapted to detect new diseases to increase readiness for future
pandemics. The advances in awareness and acceptance of testing for infections at
scale, and the technology platforms developed will have an ongoing benefit for
COVID-19 control, reducing harm from other endemic diseases, and fighting future
pandemics.

Materials and Methods

Preparation of synthetic RNA standards
MERS and SARS-CoV-1 plasmid standards (10006623 and 10006624, Integrated
DNA Technologies, Coralville, IA) were amplified using M13 PCR primers to
generate DNA templates tagged with T7 promoter sequences. DNA templates
containing T7 promoter sequences were transcribed using Hi-T7 RNA polymerase
(M0658, New England Biolabs, Lawley, MA) following the manufacturer's protocol,
with 1 U/µL RNase inhibitor (N2611, Promega, Madison, WI) added. Following
transcription, 0.01U/µL DNase I (EN0521, ThermoFisher Scientific, Waltham, MA)
was added to each reaction, and incubated at 37°C for 15 min. RNA transcripts were
purified with Monarch RNA Cleanup Kits (T2040, New England Biolabs). RNA was
quantified on a Qubit 4 fluorometer (Q32852, RNA HS Assay Kit, ThermoFisher
Scientific, Waltham, MA), and checked for length and integrity by electrophoresis on
a 2200 TapeStation (5067 RNA ScreenTape, Agilent Technologies, Santa Clara, CA).
RNA at 10^{10} copies/µL was stored in nuclease-free water in single-use aliquots.
SARS-CoV-2 RNA was prepared and quantified as previously described (*35, 36*).
490
491 **In-house TFv1 polymerase production**

Plasmid preparation: The chimeric polymerase (TFv1) was generated by assembly PCR using genomic material from *Thermus thermophilus* (*T. th*) HB27 (ATCC BAA-163D-5™, Gaithersburg, MD) and a synthetic gene fragment derived from *Thermodesulfatator indicus* (*T. in*), (Integrated DNA Technologies, Coralville, IA), similar to the method previously described (*37*). Briefly, a 3' terminal fragment of the *T. th* HB27 *polA* gene downstream of the finger domain was amplified by PCR using Phusion® Hot Start Flex DNA Polymerase (M0535L, New England Biolabs) with a modified forward primer containing sequence overlap with the *T. in polA* gene fragment *(AA734-795, codon optimized for E. coli)*. A chimeric sequence was then generated by assembly PCR. A second *T. th* polymerase fragment, upstream of the finger domain and lacking the 3'to 5' exonuclease domains, was similarly amplified and appended to the 5' end of the chimeric fragment. The resultant sequence corresponds to a *T. th* DNA polymerase I fragment, orthologous to the Stoffel fragment of *T. aq* polymerase, with a replacement in the finger domain derived from *T. in*. This gene was then cloned into the expression vector pET His6 TEV LIC cloning vector (2B-T) (a gift from Scott Gradia, Plasmid # 29666, Addgene, Watertown, MA) by ligation independent cloning (*38*). The annealed vector and insert were transformed into T7 Express lysY/Iq Competent *E. coli* (C2987H, New England Biolabs) per the manufacturer's protocol and plated on LB 100µg/mL carbenicillin plates. Colony plasmid inserts were verified by Sanger sequencing.

Protein expression and purification: 50mL starter culture in LB broth with 100µg/mL carbenicillin was inoculated with a sequence-verified colony and incubated at 30°C overnight in a shaking incubator at 200rpm. The culture was centrifuged at 5,000 RCF for 15 min and resuspended in an equivalent volume fresh LB carbenicillin media. Flasks of 500mL LB broth with 100µg/mL carbenicillin were inoculated with 5mL each of resuspended starter culture and incubated at 37°C in a shaking incubator at 200rpm until OD_{600} of 0.4-0.6 had been achieved. Cultures were induced with 0.4mg/mL of IPTG and incubated for two hours then harvested by centrifugation at 5,000 RCF for 15 min, decanted, and stored as cell pellets at –80°C until needed. Prior to purification, cell pellets were resuspended in lysis buffer (20mM sodium phosphate pH 7.4, 80mM NaCl, 1% *(v/v)* Triton (648466 Sigma, St. Louis, MO), and 1mg/mL lysozyme from chicken egg white (Millipore Sigma, Burlington, MA)). Suspensions were heated at 37°C for 20 min, then lysed by ultrasonic disruption using a Fisherbrand™ Model 120 Sonic Dismembrator (Fisher Scientific, Waltham, MA) with two cycles of two-second pulses at 50% amplitude for 2 min, while on ice. Lysates were heat-clarified at 65°C for 20 min, followed by centrifugation at 20,000 RCF. The supernatant was collected and diluted with sample diluent buffer (20mM sodium phosphate, 1.8M NaCI, pH 7.4 for 6x stock; 5 parts supernatant to 1 part diluent buffer) and filtered with a 0.22 µm syringe filter (25-342 Olympus, Genesee Scientific, San Diego, CA). The purified clarified lysate was applied to a 1mL Hitrap Talon Crude column (Cytiva, Marlborough, MA) and enriched per manufacturer's default recommended specifications using an ÄKTA start system with the Frac30 fraction collector (Cytiva). Elution fractions were evaluated by A_{280} on a spectrophotometer (2200 Nanodrop, Fisher Scientific) using the protein's expected molecular weight (63.062 kDa) and extinction coefficient (60,850 m^2/mol) of the His-tagged polymerase. Elution fractions containing protein were diluted 1:10 with 10mM sodium phosphate and applied to a 1mL HiTrap® Heparin HP column and purified per the manufacturer's recommended specifications except for a modified binding buffer (10mM sodium phosphate and 30mM NaCl at pH 7). Fractions containing protein were concentrated and buffer exchanged into storage buffer

 (17mM Tris-HCI, 167mM KCI, 17% glycerol, pH 7.5) using an Amicon® Ultra-2
543 30K centrifugal filter (Millipore Sigma), as recommended by the manufacturer. The
544 recovered polymerase solution was then adjusted to 10mM Tris-HCI, 100mM KCI,
545 2mM DTT, 0.1% Triton X-100, 50% glycerol, pH 7.5. Polymerase purity was
546 evaluated by SDS-PAGE and spectrophotometry throughout purification.

RT-LAMP assay design

Alignment of SARS-CoV-2 sequences (available on NCBI up to January 2020) were
performed using Geneious (Auckland, New Zealand). Three sets of LAMP primers
(Harmony NC1, Harmony NC2, and Harmony NC3) were developed targeting the
22,285 – 28,517 (232 bases), 28,528 – 28,471 (213 bases), and 29,135 – 29,416 (281
bases) regions of the SARS-CoV-2 nucleocapsid phosphoprotein gene. *In silico*
analysis showed that this primer design matched 100% of SARS-CoV-2 sequences
and did not have cross-reactivity to MERS and SARS-CoV-1. We used two detection
probes, each comprised of a fluorescent probe and its complementary quencher probe.
For detection of SARS-CoV-2 RNA amplification, we used FAM labeled detection
probe and Iowa Black™ quencher probe. For detection of IAC amplification, we used
TEX 615 labeled detection probe and BHQ2 labeled quencher probe. The primer and
probe sequences are listed in T**able S2**.

Wet RT-LAMP reactions

Characterization of polymerases (**Fig. 2**) was conducted in the wet reaction format.
2µL water or SARS-CoV-2 RNA at 200 or 2000 copies/µL was added to 38µL master
mix to achieve a 40µL RT-LAMP reaction. 20x Harmony NC1, NC2, and NC3
primer mix for SARS-CoV-2 amplification each contained 20µM each FIP/BIP
primer, 10µM each loop primer, and 4µM each F3/B3 primer. 20x IAC primer stock
contained 10µM loop primer. 20x probe/quencher mix for SARS-CoV-2 or IAC
amplification contained 4µM fluorophore probes and 6µM quencher probes).
Depending on the experimental design, each RT-LAMP reaction contained 1x each
primer mix or only 1x NC1 primer mix, 1x each probe or only 1x FAM probe, 2.5%
(*v/v*) mannitol (OPS Diagnostics EXMN 500-01), 5mM DTT, 0.6U/µL WarmStart
RTx, 0.7µg TFv1 DNA polymerase or 0.32U/µL Warmstart DNA polymerase 2.0 (M
0538, New England Biolabs), 1.4mM each dNTP, 1U/µL RNase inhibitor (N2615,
Promega), 25mU/µL thermostable inorganic pyrophosphatase (M0296L, New
England Biolabs), 250 copies/µL IAC DNA, 6mM magnesium sulfate, 1x ThermoPol
buffer (B9004S, New England Biolabs) in nuclease-free water. RT-LAMP reactions
were incubated at 63.3°C and FAM and/or Texas Red signal was read every 13s for
1h using a CFX96 thermal cycler (Bio-Rad).

Lyophilization of RT-LAMP reagents

Reactions containing 2x primers (2µM each FIP/BIP primer, 1µM each loop primer,
and 0.4µM each F3/B3 primer) and probes (0.4µM fluorophore probes and 0.6µM
quencher probes) in the presence of 5% *(v/v)* mannitol, 10mM DTT, 1.4µg TFv1
DNA polymerase, 1.2U/µL WarmStart RTx, 2.8mM each dNTP in 10mM Tris-HCl,
pH 7.4, 2U/µL RNase inhibitor, 50mU/µL thermostable inorganic pyrophosphatase,
and 500 copies/µL IAC DNA were prepared in 20µL aliquots of 0.2mL reagent tubes
and lyophilized. Packages were stored in desiccant packets at -20°C until use.

Harmony RT-LAMP reaction setup

Lyophilized reagents were resuspended in a final volume of 40μL containing 1x
rehydration buffer (1x ThermoPol buffer (B9004S, New England Biolabs), 6mM
supplemental $MgSO_4$, and 0.5% *(v/v)* Triton X-100). For analytical sensitivity
experiments, 2μL SARS-CoV-2 RNA in water was added. For clinical testing, 10μL
extracted RNA was added to each RT-LAMP reaction. For testing the XPRIZE
contrived specimens or VTM in direct-to-amplification experiments, 10μL sample
(not extracted) was added to each RT-LAMP reaction. For usability testing, 40μL
swab eluate was added directly to the RT-LAMP reaction using transfer pipettes or
the in-house unified dispensers.
600
601 **Analytical sensitivity of RT-LAMP assay**
602 Analytical sensitivity of lyophilized RT-LAMP was tested using purified RNA (0-
603 2×10^6 copies/40μL reaction). We also tested the effect of salt, human DNA, and
604 mucin on amplification of SARS-CoV-2 RNA and IAC DNA using simulated nasal
605 matrix as previously described (*39*).
606
Preparation of contrived swab samples and kits for usability testing
For the transfer pipette workflow, each kit contained one swab (either positive or
negative), a vial (10-500-25, Fisher Scientific, Waltham, MA) containing 400μL of 1x
rehydration buffer (see section RT-LAMP reaction setup), and one lyophilized RT-
LAMP reagent tube. For positive swabs, 10μL of 100 copies/μL SARS-CoV-2 DNA
in 0.05% Triton X-100 was pipetted onto the swab (1804-PF, Puritan Medical) and
dried at room temperature in an air-clean chamber (825-PCR/HEPA, Plas-Labs,
Lansing, NI) for 4 hours before packaging in a sealed foil pouch with desiccant (S-
8032, ULINE). The unified sampler was built from parts using an assembly jig
(custom order from Hygiena, LLC, Camarillo, CA). The unified dispenser contained a
hollow-shaft polyurethane swab attached to a bulb preloaded with 400μL 1x
rehydration buffer and a separate tube with a filter and drip dispenser friction fit
inside the tube. Each custom sampler kit contained an in-house assembled dispenser
unit and one lyophilized RT-LAMP reagent tube.
621
Usability study
The Harmony usability study was approved by the Institutional Review Board at the
University of Washington (IRB#: STUDY00010884), and informed consent was
provided by participants. HCWs (*n = 10*), including registered nurses, medical
students, and dental students were enrolled in this study over the course of 1 month.
All data was collected without identifiers. The primary objective of this study was to
determine the accuracy and precision of the two sample transfer methods and test if
variation in reproducibility impacted assay performance, and the secondary objective
was to gather user input on the feasibility of each protocol. Participants first received
an explanation of the test and its intended use, then watched an instructional video
narrated by the facilitator to become familiar with the Harmony workflow (**Movie S1**
and Movie S2). After watching the video, participants were given a packet with a
unique identifier that contained comprehensive instructions for the study procedures
and survey questions. Study procedures were modeled on a coaching methodology
(*40*) to allow natural progression of the procedures and to identify blocking steps in
the instructions. The facilitator sat 10 feet from the participant and kept a record of
verbal questions and comments from participants but did not provide answers to
procedural questions unless the participant could not proceed.
640

For part 1, data related to user preference on sample preparation, tube sizes, and their level of confidence in performing each task were collected anonymously as prompts within their study packet. Open-ended questions were extracted for themes in errors or issues and supplemented with comments and observations recorded by the facilitator. Samples were saved with de-identified labels, and after all participants had completed the study facilitators measured volumes in each receiving tube from part 1. The variances of the volume recovered by each method were tested for their equality using F-Test, and the P-value was reported. The means of the recovered volumes transferred by LPs or HCWs were compared using Student's *t*-test (two-sided), and the *p*-value was reported.

For part 2, each participant followed instructions in the packet and on the integrated mobile phone to complete the entire Harmony workflow on four total contrived samples (two samples using the transfer pipette protocol and two using the unified sampler system). Kits were prepared as specified above.

The lab personnel (*n = 5*) portion of the user testing aimed to compare performance of the Harmony device by HCW to that of an "experienced" population, by replicating this process with four students and a researcher from the Lutz Lab. Survey questions were omitted for this group because these volunteers provided feedback throughout the development of Harmony and their views are included in the discussion of this manuscript. The accuracies of tests performed by LPs and HCWs using each method were tested for their equality using Z-test (two-sided), and the *p*-value was reported.

Clinical nasal swab specimens from individuals presenting respiratory symptoms
A minimum sample size of 30 (each negative and positive) was required to achieve the confidence interval (**CI**) of 90 -100% (binomial cumulative distribution function) should all results be accurate. Our clinical specimen panel (*n = 110*) was previously used to evaluate other SARS-CoV-2 assays (*35*), but 9 specimens had insufficient volume for RNA extraction and were thus excluded from the study. These specimens were collected with informed consent as part of the Seattle Flu Study, approved by the Institutional Review Board at the University of Washington (IRB#: STUDY0006181). Thermo Fisher's OpenArray is an arrayed RT-qPCR system capable of detecting up to 26 pathogens simultaneously in a semi-quantitative manner. Specimens from the Seattle Flu Study that had other respiratory pathogens detected using the OpenArray platform were used to determine cross reactivity with Harmony. All participant specimens were de-identified prior to the transfer to the Lutz Lab at the University of Washington for analysis. The remaining 101 specimens were evaluated using the newly extracted RNA for analysis by RT-qPCR and Harmony system, to avoid variations introduced from different batches of extraction. RNA was extracted from clinical nasal swab specimens stored in viral transport media using the QIAamp Viral RNA Mini Kit (52906; Qiagen, Hilden, Germany). Prior to extraction, 100µL of each specimen was mixed with 40µL negative VTM to reach the suggested 140µL sample volume. RNA was extracted according to the manufacturer's protocol, eluted into 70µL of EB buffer, and stored at -80°C in single-use aliquots until amplification. 5µL of RNA was used for analysis in 20µL RT-qPCR using U.S. CDC N1, N2, or RP human control assays (*23*). 10µL of RNA was used for analysis in 40µL lyophilized RT-LAMP in the Harmony workflow. Each sample was run in duplicate. Only samples with positive results from both Harmony replicates were reported as positive for SARS-CoV-2. Sensitivity (TP/(TP + FN)), specificity

(TN/(TN+FP)), and concordance ((TP+TN)/(TP+TN+FP+FN)) were calculated and reported with 95% CI using binomial exact proportions.

XPRIZE contrived sample panel

The blinded panel was assembled and distributed by HudsonAlpha Discovery (Huntsville, AL) for the COVID-19 XPRIZE competition, and information on the samples was revealed to the authors only after results were submitted to XPRIZE. Samples were shipped to the Lutz Lab at the University of Washington. We reported results for contrived samples of chemically inactivated SARS-CoV-2 viral particle (ZeptoMetrix Corporation, Buffalo, NY) spiked in phosphate-buffered saline (**1x PBS**) (*n = 29*), nasal specimens (*n = 20*), or saliva (*n = 20*) at 0 to 1000 copies/reaction. All samples came in liquid form. We added 10μL sample and 30μL Harmony rehydration buffer to rehydrate each lyophilized reagents and tested across 7 different Harmony devices. Each sample was originally tested once for each sample. To affirm the identity of these specimens, we also performed RT-qPCR using CDC primer/probes after the samples had been tested using the Harmony system. To improve our confidence in reporting sensitivity and specificity, we tested two additional replicates for each sample to achieve a total of triplicates.

Housing

The housing combines the heater/reader assembly with the cell phone, while concealing the connector cables and presenting a sturdy and easy-to-use platform. The 3D CAD program, Fusion 360 (AutoDesk), was used for the design of housing. Prototypes were printed in PLA plastic (Overture™ Filament, OVPLA175) using a Prusa i3 MK3s at 0.3mm layer height. Power was supplied to both the heater/reader assembly and the phone simultaneously using a Charge-Plus USB-C (LAVA Computer Manufacturing Inc.) connector device and a standard fast-charging American cellphone charger. The LAVA device also facilitates the transfer of data between the devices.

Reader/heater device

The aluminum block to house the reagent tubes was custom-made by Bryan Willman according to the specifications in **Fig. S3**. The circuit boards were designed using Autodesk Eagle (San Rafael, CA), and the assembly of the circuit boards are shown in **Fig. S4** and **Fig. S5**. The lid, latch, and upper and lower housing of the device were drawn using SolidWorks (Dassault Systèmes, Waltham, MA) and printed by Xometry - HP MultiJet Fusion 3D (Gaithersburg, MD). All parts were assembled as shown in **Fig. S6**.

Real-time fluorescence signal analysis

After the user inserts the reaction tube into the device, the software adjusts the temperature to re-equilibrate the temperature of heat block back to the reaction temperature. During this initial period, the signals from the photo diodes (the blue LED (FAM signal for target amplification) and the yellow LED (TEX 615 signal for the IAC amplification)) are collected but not used in analyses. Once the initial period is over, signal analysis commences. Each signal is analyzed in real time by comparing the current mean of the signal over the most recent 60s interval to the signal's behavior some 360s in the past. Specifically, the current mean is compared to a bound consisting of the signal's mean over the period from 420s to 360s in the past plus a

multiple (1.9x for target, 1.5x for IAC) of the signal's sample standard deviation over that same period. If the current mean exceeds the bound, and maintains that condition for at least 15s, the signal is said to have "indicated". If the signal from the target emission indicates, the presence of SARS-CoV-2 has been detected, and the software immediately reports "positive COVID-19". If the signal from the IAC emission indicates, successful amplification of the IAC has been detected. Then, if the target emission does not also indicate before the end of the run, then a "negative COVID-19" result is reported; this delay in reporting negative results provides the maximum opportunity to detect low concentrations of SARS-CoV-2 that may be present in samples. If neither the target emission nor the IAC emission is detected, "test failed" is reported.

References

1. D. Cucinotta, M. Vanelli, WHO Declares COVID-19 a Pandemic. *Acta bio-medica : Atenei Parmensis* **91**, 157-160 (2020).
2. World Health Organization, 2021, "WHO Coronavirus (COVID-19) Dashboard." 10 August, 2021 https://covid19.who.int/.
3. A. Sandford, 2020, "Coronavirus: Half of humanity now on lockdown as 90 countries call for confinement." Euronews, 10 August, 2021 https://www.euronews.com/2020/04/02/coronavirus-in-europe-spain-s-death-toll-hits-10-000-after-record-950-new-deaths-in-24-hou.
4. G. Bonaccorsi *et al.*, Economic and social consequences of human mobility restrictions under COVID-19. *Proc Natl Acad Sci U S A* **117**, 15530-15535 (2020).
5. R. A. Teran *et al.*, Postvaccination SARS-CoV-2 Infections Among Skilled Nursing Facility Residents and Staff Members - Chicago, Illinois, December 2020-March 2021. *MMWR. Morbidity and mortality weekly report* **70**, 632-638 (2021).
6. C. M. Brown *et al.*, 2021, "Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021." US CDC, 10 August, 2021 https://www.cdc.gov/mmwr/volumes/70/wr/mm7031e2.htm?s_cid=mm7031e2_w#contribAff.
7. Centers for Disease Control and Prevention, 2021, "Requirement for Proof of Negative COVID-19 Test or Recovery from COVID-19 for All Air Passengers Arriving in the United States." 10 August, 2021 https://www.cdc.gov/coronavirus/2019-ncov/travelers/testing-international-air-travelers.html.
8. E. Kline *et al.*, 2021, "Multiplex target-redundant RT-LAMP for robust detection of SARS-CoV-2 using novel fluorescent universal displacement probes." medRxiv, (2021)
9. V. L. Dao Thi *et al.*, A colorimetric RT-LAMP assay and LAMP-sequencing for detecting SARS-CoV-2 RNA in clinical samples. *Sci Transl Med* **12**, (2020).
10. S. Wu *et al.*, Colorimetric isothermal nucleic acid detection of SARS-CoV-2 with dye combination. *Heliyon* **7**, e06886 (2021).
11. J. Xu *et al.*, Room-temperature-storable PCR mixes for SARS-CoV-2 detection. *Clin Biochem* **84**, 73-78 (2020).
12. N. Panpradist *et al.*, OLA-Simple: A software-guided HIV-1 drug resistance test for low-resource laboratories. *EBioMedicine* **50**, 34-44 (2019).
13. N. Panpradist *et al.*, Near point-of-care, point-mutation test to detect drug resistance in HIV-1: a validation study in a Mexican cohort. *AIDS*, (2020).

14.   J. Vrana *et al.*, OLA Simple v 1.0: observational study of an app-guided HIV
drug resistance test at the Coptic Hope Center in Kenya. *medRxiv*, (2021).

15.   B. Moon, M. Jones, J. Valdez, 2003, "Lyophilized beads containing
mannitol." Cepheid, 10 August, 2021
https://patents.google.com/patent/US20050069898A1/en.

16.   D.-C. Nyan *et al.*, Rapid Detection of Hepatitis B Virus in Blood Plasma by a
Specific and Sensitive Loop-Mediated Isothermal Amplification Assay. *Clinical*
Infectious Diseases **59**, 16-23 (2014).

17.   A. N. Spiess, N. Mueller, R. Ivell, Trehalose is a potent PCR enhancer:
lowering of DNA melting temperature and thermal stabilization of taq polymerase by
the disaccharide trehalose. *Clin Chem* **50**, 1256-1259 (2004).

18.   Y. Mori, K. Nagamine, N. Tomita, T. Notomi, Detection of loop-mediated
isothermal amplification reaction by turbidity derived from magnesium
pyrophosphate formation. *Biochem Biophys Res Commun* **289**, 150-154 (2001).

19.   K. Tone, R. Fujisaki, T. Yamazaki, K. Makimura, Enhancing melting curve
analysis for the discrimination of loop-mediated isothermal amplification products
from four pathogenic molds: Use of inorganic pyrophosphatase and its effect in
reducing the variance in melting temperature values. *J Microbiol Methods* **132**, 41-45
(2017).

20.   S. Xie, Y. Yuan, Y. Chai, R. Yuan, Tracing Phosphate Ions Generated during
Loop-Mediated Isothermal Amplification for Electrochemical Detection of Nosema
bombycis Genomic DNA PTP1. *Anal Chem* **87**, 10268-10274 (2015).

21.   I. New England Biolabs, 2021, "Thermostable Inorganic Pyrophosphatase." 10
August, 2021 https://www.neb.com/products/m0296-thermostable-inorganic-
pyrophosphatase#Product%20Information.

22.   T. Lennox, B. E. Slatko, L. E. Sears, 1995, "Purified thermostable inorganic
pyrophosphatase obtainable from thermococcus litoralis " New England Biolabs Inc,
19 August, 2021 https://patents.google.com/patent/US5861296A/en.

23.   U.S. Centers for Disease Control and Prevention, 2020, "CDC 2019-Novel
Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel For Emergency Use
Only." U.S. Food and Drug Administration, 10 August, 2021
https://www.fda.gov/media/134922/download.

24.   C. Thermo Fisher Scientific, 2021, "OpenArray Technology Overview." 10
August, 2021 https://www.thermofisher.com/us/en/home/life-science/pcr/real-time-
pcr/real-time-openarray/open-array-technology.html.

25.   C. B. F. Vogels *et al.*, SalivaDirect: A simplified and flexible platform to
enhance SARS-CoV-2 testing capacity. *Med (N Y)* **2**, 263-280.e266 (2021).

26.   R. Wolfel *et al.*, Virological assessment of hospitalized patients with COVID-
2019. *Nature* **581**, 465-469 (2020).

27.   J. Zhu, J. Guo, Y. Xu, X. Chen, Viral dynamics of SARS-CoV-2 in saliva
from infected patients. *J Infect* **81**, e48-e50 (2020).

28.   B. Pang *et al.*, Isothermal Amplification and Ambient Visualization in a Single
Tube for the Detection of SARS-CoV-2 Using Loop-Mediated Amplification and
CRISPR Technology. *Analytical Chemistry* **92**, 16204-16212 (2020).

29.   P. Craw, W. Balachandran, Isothermal nucleic acid amplification technologies
for point-of-care diagnostics: a critical review. *Lab Chip* **12**, 2469-2486 (2012).

30.   E. Gonzalez-Gonzalez *et al.*, Colorimetric loop-mediated isothermal
amplification (LAMP) for cost-effective and quantitative detection of SARS-CoV-2:
the change in color in LAMP-based assays quantitatively correlates with viral copy
number. *Anal Methods* **13**, 169-178 (2021).

31.   J. Rodriguez-Manzano *et al.*, Handheld Point-of-Care System for Rapid
Detection of SARS-CoV-2 Extracted RNA in under 20 min. *ACS Cent Sci* **7**, 307-317
(2021).
32.   Chaibio. (Santa Clara, CA).
33.   W. Putri, D. J. Muscatello, M. S. Stockwell, A. T. Newall, Economic burden
of seasonal influenza in the United States. *Vaccine* **36**, 3960-3966 (2018).
34.   Centers for Diseases Control and Prevention. (2012).
35.   N. Panpradist *et al.*, Simpler and faster Covid-19 testing: Strategies to
streamline SARS-CoV-2 molecular assays. *EBioMedicine* **64**, 103236 (2021).
36.   G. Gulati *et al.*, Inexpensive workflow to enable simultaneous monitoring of
HIV viral load and detection of SARS-CoV-2 infection. *medRxiv*, (2021).
37.   N. Morant, University of Bath, (2015).
38.   Addgene, "Ligation Independent Cloning." 8 April, 2021
https://www.addgene.org/protocols/lic/.
39.   N. Panpradist *et al.*, Swab sample transfer for point-of-care diagnostics:
characterization of swab types and manual agitation methods. *PLoS One* **9**, e105786
(2014).
40.   R. Mack, J. B. Robinson, in *The Psychology of Expertise,* H. R.R., Ed.
(Springer, New York, NY, 1992), pp. 245-268.
41.   FPbase, 2021, "Spectra viewer." 20 June, 2020
https://www.fpbase.org/spectra/.
42.   Newport, 2021, "Optical Filters." 4 March, 2021
https://www.newport.com/c/optical-filters.
43.   Mousers Electronics, 2021, "LED lighting." 4 March, 2021
https://www.mouser.com/Optoelectronics/LED-Lighting/_/N-74g9t.
44.   A. Alekseenko *et al.*, Direct detection of SARS-CoV-2 using non-commercial
RT-LAMP reagents on heat-inactivated samples. *Sci Rep* **11**, 1820 (2021).
45.   B. A. Rabe, C. Cepko, SARS-CoV-2 detection using isothermal amplification
and a rapid, inexpensive protocol for sample inactivation and purification. *Proc Natl*
Acad Sci U S A **117**, 24450-24458 (2020).
46.   S. Wei *et al.*, Direct diagnostic testing of SARS-CoV-2 without the need for
prior RNA extraction. *Sci Rep* **11**, 2402 (2021).
47.   L. Bokelmann *et al.*, Point-of-care bulk testing for SARS-CoV-2 by
combining hybridization capture with improved colorimetric LAMP. *Nat Commun*
12, 1467 (2021).
48.   W. Yamazaki, Y. Matsumura, U. Thongchankaew-Seo, Y. Yamazaki, M.
Nagao, Development of a point-of-care test to detect SARS-CoV-2 from saliva which
combines a simple RNA extraction method with colorimetric reverse transcription
loop-mediated isothermal amplification detection. *J Clin Virol* **136**, 104760 (2021).
49.   J. Qian *et al.*, An enhanced isothermal amplification assay for viral detection.
Nat Commun **11**, 5920 (2020).
50.   M. Patchsung *et al.*, Clinical validation of a Cas13-based assay for the
detection of SARS-CoV-2 RNA. *Nat Biomed Eng* **4**, 1140-1149 (2020).
51.   J. Joung *et al.*, Point-of-care testing for COVID-19 using SHERLOCK
diagnostics. *medRxiv*, (2020).
52.   J. P. Broughton *et al.*, CRISPR-Cas12-based detection of SARS-CoV-2. *Nat*
Biotechnol **38**, 870-874 (2020).
53.   I. Mammoth Biosciences, 2020, "INSTRUCTIONS FOR USE SARS-CoV-2
DETECTRTM Reagent Kit." 10 August, 2021
https://www.fda.gov/media/141765/download.

54. UCSF Health Clinical Laboratories UCSF Clinical Labs at China Basin, 2020,
"SARS-CoV-2 RNA DETECTR Assay " 10 August, 2021
https://www.fda.gov/media/139937/download.
55. I. MobileDetect Bio, 2020, "MobileDetect-BIO BCC19 Test Kit for SARS-
CoV-2 Detection." 2021, 10 August, 2021
https://www.fda.gov/media/141791/download.
56. I. MobileDetect Bio. (2021), vol. 2021.
57. SEASUN BIOMATERIALS Inc., 2021, "AQ-TOP™ COVID-19 Rapid
Detection Kit PLUS." 10 August, 2021
https://www.fda.gov/media/142800/download.
58. I. Sherlock Biosciences, 2021, "INSTRUCTIONS FOR USE SherlockTM
CRISPR SARS-CoV-2 kit." 10 August, 2021
https://www.fda.gov/media/137746/download.
59. I. Color Health, 2021, "Color SARS-CoV-2 RT-LAMP Diagnostic Assay
EUA Summary." 10 August, 2021 https://www.fda.gov/media/138249/download.
60. Lucira Health, 2021, "Lucira™ CHECK-IT COVID-19 Test Kit." 10 August,
2021 https://www.fda.gov/media/147494/download.
61. D. MitraIvan, K. Dimov, J. R. Waldeisen, 2015, "Colorimetric Detection of
Nucleic Acid Amplification." 10 August, 2021
https://patents.google.com/patent/US20170044599A1/pt-pt.

Acknowledgments

We thank Bryan Willman for his support in fabricating customized heat blocks, Jan
Gray for his help with firmware development, Tom Blank for sharing the PCB
fabrication resources, and Dr. Liz Sanocki for the useful feedback on the software
user interface. We thank Shawna Cooper for sharing the graphics and content used in
Audere's mobile app's flu@home, which influenced the design of the first few
screens of the Harmony COVID-19 software. We thank Dr. Paul Yager and Steven
Bennett for use of their optical filters during the initial stage of device development.
We thank Jason Tauscher at the Washington Nanofabrication Facility for his
assistance in cutting the plastic sheet filters. The Washington Nanofabrication Facility
is a National Nanotechnology Coordinated Infrastructure (NNCI) site at the
University of Washington with partial support from the National Science Foundation
via awards NNCI-2025489 and NNCI-1542101. We thank Seattle Flu Study
researchers Dr. Jay Shendure and Dr. Jase Gehring for their helpful technical
discussion. We thank Dr. Syamal Raychaudhuri, Dr. Frances Chu from Inbios
International, and Dr. Gwong-Jen J. Chang for the stimulating discussion. We thank
the Seattle Flu Study and the Seattle Coronavirus Assessment Network (SCAN) teams
led by Principal Investigators: Helen Y. Chu, MD, MPH, Michael Boeckh, MD, PhD,
Janet A. Englund, MD, Michael Famulare, PhD, Barry R. Lutz, PhD, Deborah A.
Nickerson, PhD, Mark J. Rieder, PhD, Lea M. Starita, PhD, Mathew Thompson, MD,
MPH, DPhil, Jay Shendure, MD, PhD and Trevor Bedford, PhD for providing
specimens for testing.
934
Funding: This work was supported by the Seattle Flu Study (funded by Gates
Ventures) and the National Institutes of Health (R01AI140845; 5R61AI140460-03).
We thank the Washington Entrepreneurial Research Evaluation and
Commercialization HUB program (WE-REACH, U01 HL152401) and their matching
grant partners for partly supporting reagents, supplies, and personnel. ITH was

supported in part by the National Institute of General Medical Sciences of the
National Institutes of Health under Award Number T32GM008268.
This work does not reflect the views of the funders. The funders were not involved in
the design of the study, and funders do not have any ownership over the management
and conduct of the study, the data, or the rights to publish.
945

Author contributions: NP developed lyophilized RT-LAMP and outlined the overall
plan for experiments and data visualization presented in this manuscript. RGA
developed a mobile software application for operating the device and analyzing
results in real-time. MR developed the heater and fluorescent reader device. EK
designed the RT-LAMP assay primers and probes and engineered polymerase. EK,
ITH and QW synthesized polymerase and provided usability feedback during the
development of the Harmony COVID-19 system. ITH and QW prepared *in vitro* RNA
transcripts. JHK and VL led the usability study. NP, AKO, and CB tested clinical and
contrived specimens. RGA, NP, AKO, SDG, and JHK analyzed the data. ITH and
QW prepared the kits and blinded mock samples for usability testing. DL developed
housing units to integrate the cell phone, sample preparation station, and the device.
LMS and PDH designed and characterized the clinical specimen panel used in this
study. PKD provided technical insights. MT oversaw the usability study. BRL
oversaw the development and evaluation of the Harmony COVID-19 system. All
authors contributed to writing this manuscript and approved the final version.
961

Competing interest: Provisional patent applications have been filed on several
components of the Harmony COVID-19 system. NP, RGA, MR, EK, QW, ITH, DL,
and BRL are inventors on one or more provisional patent applications. NP, RGA,
MR, EK, QW, ITH, JHK, AKO, CB, DL, and BRL hold equity in a startup company
that has licensed related technology and supports ongoing work in the BRL laboratory
at the University of Washington but played no role in the study. MT is on the
Advisory Board for Visby Medical which produces tests for COVID-19 and has
received reimbursement for this work. He has also received reimbursement for
medical advice to Roche Molecular Diagnostics and Inflammatix.
971

972   **Data and materials availability:** All data are presented in the main text and
973   supplementary information.
974

Code availability: Sequence alignment and primer design was performed using
Geneious 8.1.9 (Auckland, New Zealand). CFX Maestro (Bio-Rad, Hercules, CA)
was used to analyze the RT-PCR results. TapeStation Software (Agilent, Santa Clara,
CA) was used to visualize fragments of synthetic RNA. A provisional patent
application was filed regarding aspects of the cell phone application. The data
analysis algorithm is described in the manuscript.
981

982   **Figures and Tables**

Line	
983	
984	**Fig. 1 Harmony COVID-19 workflow, analytical performance, and**
985	**interpretation.**
986	(**A**) User workflow. A nasal swab is collected and eluted in the rehydration buffer
987	using either a unified sampler-dispenser (shown) or a tube-and-bulb method (**Fig. 8**).
988	The swab eluate is then transferred into the reaction tube to rehydrate lyophilized, pre-
989	loaded RT-LAMP reagents. Users follow the instructions on the cell phone app to
990	record the sample identity, insert the tube in the test slot, and close the device. Four
991	samples can be analyzed in parallel. (Photo credits: (A)1-(A)4, Mark Stone at the
992	University of Washington and (A)5, Christopher Snyder at North Seattle College). (**B**)
993	Examples of on-device analysis. Lyophilized reagents were rehydrated with the eluate
994	from swabs spiked with 0, 200, 2000, or 20,000 copies of SARS-CoV-2 RNA, run on
995	the device, and analyzed in real-time. The samples with SARS-CoV-2 RNA at 2000,
996	200, and 20 copies/reaction (**rxn**) were reported as positive by software at 27 min, 30
997	min, and 41 min, respectively; after 60 min the NTC reaction was classified as
998	negative. (**C**) Time-to-result. Individual detection time points (*n = 3*) are plotted.
999	Variation in detection time increases as samples approach the detection limit. (**D**)

1000 Diagnostic algorithm. Harmony COVID-19 software calls samples as positive,
1001 negative, or indeterminate based on detection of the three regions in the nucleocapsid
1002 gene (Harmony NC1 overlapping with the CDC N1 region, Harmony NC2
1003 (overlapping with CDC N3 region excluded from the current kit), and Harmony NC3
1004 overlapping with the CDC N2 region) and the engineered IAC sequence.
1005

1006

A SARS-CoV-2 NC1 assay (single-plex RT-LAMP with probe detection)

B SARS-CoV-2 RNA amplification in 4-plex RT-LAMP with probe detection

C IAC DNA amplification in 4-plex RT-LAMP with probe detection

1007
Fig. 2 Comparison of RT-LAMP using TFv1 polymerase vs commercial Bst
polymerase using conventional RT-qPCR machine. (**A**) FAM signal of the RT-
LAMP assay using fresh reagents (not lyophilized) containing only NC1 primer set (6
primers total) and SARS-CoV-2 detection probe and quencher with 0, 400, or 4000
SARS-CoV-2 RNA copies/reaction (corresponding to 0, 100, or 1,000 SARS-CoV-2
RNA copies/μL, respectively). (**B**) FAM signal and (**C**) IAC signal of the 4-plexed
RT-LAMP assay using fresh reagents containing all primers (18 SARS-CoV-2
primers and 1 IAC primer), SARS-CoV-2 detection probe and quencher, and IAC
detection probe and quencher with 0, 400, or 4000 SARS-CoV-2 RNA
copies/reaction (corresponding to 0, 100, or 1,000 SARS-CoV-2 RNA copies/μL,
respectively). For (**C**) only NTC is shown to indicate true negative. All reactions were
incubated at 63.3 °C for 1 hour and read every 13s in commercial thermal cycler.
1020

1021

1022
1023
Fig. 3 Lyophilized RT-LAMP and its analytical sensitivity.
(**A**) To set up the assay, a sample in elution/rehydration buffer containing
magnesium, Thermopol buffer, and detergents is added to rehydrate the lyophilized
RT-LAMP reagents in a single step. (**B**) Real-time amplification signal of RT-LAMP
reactions containing SARS-CoV-2 RNA (**NTC**; no template control), 10, 15, 20, 200,

2000, 2×10^4, or 2×10^5 copies/40μL reaction (**rxn**). The left panel shows the average (*n*
= 3) FAM signal detecting SARS-CoV-2. *Only 2/3 replicates of 10 copies/rxn
amplified so the average was from duplicate reactions. The right panel shows TEX
615 signal detecting the internal amplification control (IAC). The IAC was detected in
the NTC (*n* = 3) and in the single 10 copies/reaction that did not detect SARS-CoV-2.
(**C**) Time to detection of SARS-CoV-2 and IAC targets reported by the real-time
thermal cycler. Individual data points are plotted. Note that only 2/3 replicates of 10
copies/reaction amplified. IAC signals were properly detected in NTC (*n* = 3) and 1
of the 3 replicates of 10 copies/reaction undetected for SARS-CoV-2. (**D**) Evaluation
of analytical sensitivity at 20 copies/reaction of SARS-CoV-2 RNA (*n* = *40*),
performed in two different runs (*n* = *20* each) with two different serially diluted RNA
samples. Time-to-result of individual samples are plotted along with medians (middle
lines of the boxes), interquartile ranges (edges of the boxes), ranges (the ends of
whiskers), and outliers (data points outside the whiskers). (**E**) Impact of nasal matrix.
SARS-CoV-2 RNA at 0, 40, or 100 copies/reaction (corresponding to 0, 1, or 2.5
copies/μL) was amplified in lyophilized RT-LAMP in the presence of simulated nasal
matrix (*n* = *3*). All data was measured every 13s using FAM and TEX 615 channels,
by a real-time thermal cycler in 1h reactions at 63.3°C, and (**C**).
1047

1048
1049

1050
1051 **Fig. 4 Overview of Harmony COVID-19 hardware.**
1052 (**A**) Plastic case cradles the cell phone (removable and connected by a spring cable),
1053 mounts the heater/reader device, and houses a Charge-Plus USB-C connector hub (not

shown). A sample station holds the sample and reaction tube during processing and is detachable to allow cleaning. Weight: 266g housing, 104g heater/reader device (total <0.5kg). Dimensions: 205mm x 167.5mm x 125mm housing, 30mm x 120mm x 50mm heater/reader device. (**B**) The heater/reader device contains an aluminum block with wells for four samples (0.2mL reagent tubes) and is heated from the bottom by a resistive heater made from serpentine conductive traces on a printed circuit board. In the middle of the heater, a temperature sensor (Class B Platinum RTD) is used to measure the heat block temperature. Power to the heater is supplied by a MOSFET and modulated by varying the PWM duty cycle of the MOSFET. (**C**) Temperature profile after the lid opening throughout a 60-min assay run. The microcontroller (die) is measured to ensure the electronics are not overheated. (**D**) Lid heater, LED, and detector. A heater (85°C) on top of the tube prevents condensation on the tube lid. The lid heater is spring loaded to apply a preload force to the tubes to ensure good thermal contact and contains pass-through holes for excitation LEDs. (**E**) Spectral characteristics of the detection system. Blue and yellow LEDs provide excitation for FAM and TEX 615, respectively, and photodetectors on each side detect light passing through emission filters (spectral information from manufacturers(*41-43*)). The LEDs are operated independently (only one LED is illuminated at a given time). (**F**) Effect of thermostable inorganic pyrophosphatase (**TiPP**) on RT-LAMP signal in the Harmony device. Normalized signal of negative control samples using the RT-LAMP formulation with and without TiPP (*n = 1* each) at 64°C.

1076
1077

1078
1079
Fig. 5 Cell phone user interface and result reporting.
The Android Harmony application guides the user through steps to set up and run the
test. (**A**) Intended use of the device. (**B**) Instructions for the user to prepare samples.
(**B**) Selection of the number of samples. (**D**) Collection of sample identifiers by
barcode, photo capture, or manual typing. (**E**) Instruction to insert the tube when the
temperature of the device reaches the reaction temperature. (**F**) Real-time analysis
during the test run. (**G**) Positive results are reported as soon as they are detected. (**H**)
Negative and IND results are reported at the end of the run time.
1088

1089

D

Sample matrix	TP	TN	FP	FN	Sensitivity	Specificity
1x PBS	52	6	0	2	**96%** (95%CI: 87-100)	100%
Nasal swabs	35	6	0	1	**97%** (95%CI: 85-100)	100%
Saliva	30	6	0	6	**83%** (95%CI: 67-93)	100%

95% CI (Bionomial Exact)

1090
Fig. 6 Analysis of XPRIZE contrived sample panel without RNA extraction. (**A**) Viral
particles spiked in 1xPBS were tested in triplicate for each sample (n = 9 total for
positive sample concentrations and n = 6 total for negative samples). (**B**) Viral
particles spiked in human nasal matrix were tested in triplicate (n = 6 total for each
concentration). (**C**) Viral particles spiked in saliva (n = 6 total for each concentration).
(**D**) Summary table for the sensitivity and specificity of the Harmony COVID-19
system on the XPRIZE contrived samples. Concentrations of viral particles are the
final concentrations in each 40uL reaction. Threshold concentration for positive is at
20 viral particle copies/reaction (0.5 copies/µL). Contrived samples below the
positive threshold were also tested (**Fig. S7**). Real-time amplification curves of these
data are in **Fig. S8.** Reactions were set up either at room temperature (*hollow*) or on
ice (*solid*).
1103

A

RNA extracted from nasal swabs collected from individuals presenting with respiratory symptoms tested by Harmony system

□ Negative by Harmony　◇ Positive by Harmony

Negative by RT-PCR (undetectable by CDC N1 or N2 assay) | INC | < 0.5 | ≥ 0.5

SARS-CoV-2 RNA (copies/µL)

B Summary of Harmony performance on RNA extracted from nasal VTM specimens

Positive thresholds (copies/µL)	TP	TN	FP	FN	Sensitivity	Specificity
> 0	55	136	0	5	92% (95%CI: 82-97)	100% (95%CI: 97-100)
≥ 0.5 (1x LoD)	46	136	0	0	100% (95%CI: 93-100)	100% (95%CI: 97-100)

Counts = no. of tested samples (2 for each specimen); 95%CI (Binomial Exact)

C RNA extracted from SARS-CoV-2 negative nasal specimens tested on Harmony system

Organisms present specimens	Quantification cycle determined by OpenArray (5 10 15 20 25 30)	False positive samples by Harmony COVID-19
Adenovirus		0/3
Bocavirus		0/1
Enterovirus		0/2
Influenza		0/11
Metapneumovirus		0/1
Parainfluenza virus		0/2
Parechovirus		0/1
Pneumoniae		0/15
Rhinovirus		0/26
Seasonal Coronavirus		0/6

D Nasal specimens in VTM tested by Harmony system without extraction

□ Negative by Harmony　◇ Positive by Harmony　○ IND by Harmony

Neg | INC | < 0.5 | ≥ 0.5, <1 | ≥ 1

SARS-CoV-2 RNA (copies/µL)

E Relative difference vs Mean; +1.96SD, bias, -1.96SD

F Summary of Harmony performance on nasal VTM specimens without extraction

Positive threshold (copies/µL)	TP	TN	FP	FN	IND	Sensitivity
> 0	40	4	0	9	1	82% (95%CI: 68-91)
≥ 0.5 (1x LoD)	39	4	0	6	1	87% (95%CI: 73-95)
≥ 1 (2x LoD)	39	4	0	2	1	95% (95%CI: 83-99)

Counts = no. of tested samples (2 for each specimen); 95%CI (Binomial Exact)

Fig. 7 Harmony COVID-19 performance on clinical specimens.

(**A**) Detection time called by Harmony COVID-19 software for the analysis of purified RNA extracted from human nasal specimens from 101 patients presenting respiratory symptoms. Stored specimens were re-tested by RT-qPCR using N1 and N2 CDC primers; results matched previous results in 30 previous positive specimens (positive for N1 and N2) and 68 previous negative specimens, with three previous positive specimens classified as inconclusive (INC) because they were negative for either CDC N1 or CDC N2 by RT-qPCR. Samples are ranked from left to right by increasing SARS-CoV-2 concentrations as determined by RT-qPCR. Extracted RNA from specimens was analyzed by Harmony COVID-19 (10µL RNA in 40µL RT-LAMP dry reagents, *n = 2*). Samples were classified as positive by Harmony only if both replicates were detected. The classification results by Harmony were compared to RT-qPCR using CDC primers and probes (5µL RNA in 20µL RT-qPCR reaction). (**B**) Organisms in clinical samples collected from individuals presenting with respiratory symptoms were quantified using OpenArray, as previously described(*35*). High quantification cycle values indicate low concentrations. All these specimens

were correctly identified as SARS-CoV-2 negative by Harmony. (**C**) Summary table for the sensitivity and specificity of the Harmony COVID-19 system using extracted RNA from clinical specimens (RT-qPCR INC samples excluded). (**D**) Detection time called by Harmony COVID-19 software for the analysis on 27 VTM specimens previously tested in (A). Without the RNA extraction step, 10µL VTM was added in the final 40µL RT-LAMP rxn, (*n = 2*). Dashed line indicates the detection time at 60 min. (**E**) Bland-Altman plot of the detection time of SARS-CoV-2 positive specimens of the direct VTM group compared to the extracted RNA group. Dashed lines indicate the acceptable bound of the difference of the detection time (mean ± 1.96SD). (**F**) Summary table for the sensitivity of the Harmony COVID-19 system using VTM specimens without extraction.

Fig. 8 Usability study of Harmony COVID-19 workflow including two sample transfer methods at the POC.

(**A**) Study design. (**B**) Illustration of the first sample transfer method option using a unified dispenser, which integrates a swab, buffer container, and a dropper in a single device. The contained buffer is released to elute the swab sample by cracking a conduit, the user agitates the fluid by shaking the tube, and a dropper tip allows the use to transfer two drops of fluid to the reaction tube by squeezing the body of the device. (**C**) Illustration of the second sample transfer method including a volumetric transfer pipette ($40\mu L$), a nasal swab, and a pre-loaded buffer vial. **Movie S1** demonstrates this workflow. Briefly, swabs are manually rubbed on the side of the tube for 30 seconds, soaked for 1 minute, and removed. The pipette is then used to transfer the swab eluate to rehydrate the lyophilized RT-LAMP reaction tube. **Movie S2** demonstrates this workflow. (**D**) Volume transferred by each method performed by healthcare workers (**HCWs**) or laboratory personnel (**LPs**). Individual volume measurements are plotted along with medians (middle lines of the boxes), interquartile ranges (edges of the boxes), and ranges (the ends of whiskers). **e** and **f**, Assay performance on blinded contrived swabs (one negative swab and one positive swab with SARS-CoV-2 DNA at 1,000 copies/swab, corresponding to 100 copies/reaction) by LPs ($n = 5$) and untrained HCWs ($n = 10$) using transfer pipettes, (**E**) or unified dispensers, (**F**) The usability experiment written protocol is available on protocol.io (https://dx.doi.org/10.17504/protocols.io.bkvskw6e) and as a visual demonstration in **Movie S1 and Movie S2**. (**G**) Performance summary for the transfer pipette method. (**H**) Performance summary for the unified dispenser method.

1162 **Table 1** Feature comparison between the Harmony COVID-19 system and other assays.
1163 (**A**) Comparison to the U.S. CDC assay.(*23*) Full cost calculations for reagents and devices
1164 are enclosed in **Tables S4** and **Table S5**.

1165

Item	Standard RT-PCR assay (based on the U.S. CDC protocol)(*23*)	Covid-19 Harmony
SARS-CoV-2 primer detection	Separate reactions for N1 and N2	Multi-target redundancy amplifying three regions of the N gene in a single reaction tube
Process control	Human RP gene	Engineered internal control
LoD	1-3.2 copies/µL from extracted RNA	0.5 copies/µL (20 copies/40µL reaction) from synthetic RNA; 1 copies/µL (40 copies/40µL reaction) from extracted RNA from VTM; 2.5 copies/µL (100 copies/40µL reaction) from contrived nasal samples
Consumable cost	$12.94 / sample ($6 extraction kit and $6.94 for three RT-PCR Taq Path/IDT probes)	$8.00 / sample
Easy to use reagents	No	Yes
Batch size	24 specimens	Not required, run up to 4 samples
Equipment cost	> $5000 qPCR machine	$247 customized heater/reader
Time for sample-to-result	260 min Hands-on: 120 min Wait-time: 120 min Interpretation: 20 min	21-91 min Hands-on: 1 min for direct amplification Wait-time: 20-45 min for positive samples, but 90 min is required to confirm true negative

1166 (**B**) Comparison of Harmony COVID-19 to other isothermal assays for SARS-CoV-2.

Published assays	Amplification chemistry	Multi-target redundancy in a single tube	Reported LoD	User-friendly device with ready-to-use reagents and a closed system	Demonstration of use by HCWs
Harmony COVID-19 (This study)	RT-LAMP	Yes	0.5-2.5 copies/µL	Yes	Yes
A Alekseenko *et. al.* 2021(*44*)	RT-LAMP	No	10 copies/µL	No	No
BA Rabe and C Cepko(*45*)	RT-LAMP	No	50 copies/µL	No	No
S Wei, *et. al.*(*46*)	RT-LAMP	No	2.5 copies/µL	No	No
D Thi, *et. al.* (*9*)	RT-LAMP	No	5 copies/µL	No	No
L Bokelmann *et. al.* (*47*)	RT-LAMP	No	5-20 copies/µL	No	No
W Yamaziki *et. al.* (*48*)	RT-LAMP	Yes	25 copies/µL	No	No
J Qian *et. al.*(*49*)	RPA	Yes	0.5 copies/µL	No	No
M Patchsung *et. al.*(*50*)	SHERLOCK	No	2.1 copies/µL	No	No
J Joung *et. al.*(*51*)	SHERLOCK	No	2 copies/µL	No	No
J Broughton *et.al.* (*52*)	CRISPR cas12	No	10 copy/µL	No	No

1167
1168

Supplementary Materials

Table. S1.
Summary of RT-LAMP based technologies that have received emergency use authorization as of July 15th, 2021.

Table. S2.
Primers, probes, and control sequences.

Table. S3.
Feedback from the HCWs

Table. S4.
Detailed reagent and device cost at a production scale of 10,000 units.

Table. S5.
Consumable costs per test

Fig. S1.
Effects of excipients on fresh RT-LAMP reactions tested on a commercial real-time thermal cycler.

Fig. S2.
Cross-reactivity of MERS and SARS in lyophilized RT-LAMP.

Fig. S3.
Heat block used in Harmony COVID-19 device.

Fig. S4.
The design of optical and heater circuit boards for the Harmony COVID-19 device.

Fig. S5.
Circuit board assembly and required parts

Fig. S6.
Device assembly

Fig. S7.
Analysis of XPRIZE panel of contrived samples containing less than 20 copies/reaction.

Fig. S8.
Real-time amplification curves of samples analyzed by HARMONY Covid-19

Fig. S9.
Standard curves of RT-qPCR

Fig. S10.
Real-time amplification curves of RT-qPCR using CDC primers/probes.

Video S1 Demonstration of transfer pipette workflow incorporated with Harmony COVID-19.

Video S2 Demonstration of the integrated sampling system workflow with Harmony COVID-19